Compare TCBS & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCBS | BRNS |
|---|---|---|
| Founded | 1934 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.7M | 55.9M |
| IPO Year | N/A | 2021 |
| Metric | TCBS | BRNS |
|---|---|---|
| Price | $16.35 | $0.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 3.1K | ★ 69.0K |
| Earning Date | 11-07-2025 | 11-07-2025 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $15,268,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.75 | ★ N/A |
| Revenue Growth | 54.88 | ★ 1766.46 |
| 52 Week Low | $14.98 | $0.64 |
| 52 Week High | $19.70 | $2.92 |
| Indicator | TCBS | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 78.59 | 38.31 |
| Support Level | $16.09 | $0.68 |
| Resistance Level | $19.70 | $0.74 |
| Average True Range (ATR) | 0.62 | 0.05 |
| MACD | 0.19 | 0.02 |
| Stochastic Oscillator | 57.29 | 31.64 |
Texas Community Bancshares Inc is a holding company. The company's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations and borrowings from the Federal Home Loan Bank of Dallas, in residential real estate loans and commercial real estate loans and, to a lesser extent, commercial loans, construction and land loans, and consumer and other loans. Its portfolio segments are real estate, agriculture, commercial, consumer and other.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.